

Fenotypy/subfenotypy ARDS

Pavel Dostál

Klinika anesteziologie, resuscitace a intenzivní medicíny
Univerzita Karlova, Lékařská fakulta v Hradci Králové,
Fakultní nemocnice Hradec Králové



The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material

Intensive Care Med (2012) 38:1573–1582
DOI 10.1007/s00134-012-2682-1

Niall D. Ferguson
Eddy Fan
Luigi Camporota
Massimo Antonelli
Antonio Anzueto
Richard Beale

The ARDS conceptual model

Face validity derives from an understanding of how clinicians recognize patients with the syndrome, therefore, considerable discussion focused on developing a conceptual model of ARDS. The panel agreed that ARDS is a type of acute diffuse lung injury associated with a pre-disposing risk factor, characterized by inflammation leading to increased pulmonary vascular permeability and loss of aerated lung tissue. The hallmarks of the clinical



The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material

Intensive Care Med (2012) 38:1573–1582
DOI 10.1007/s00134-012-2682-1

Niall D. Ferguson
Eddy Fan
Luigi Camporota
Massimo Antonelli
Antonio Anzueto
Richard Beale

loss of aerated lung tissue. The hallmarks of the **clinical** syndrome are hypoxemia and bilateral radiographic opacities [23] (using standard chest X-ray or computed tomography [CT] scan), associated with several physiological derangements including: increased pulmonary venous admixture, increased physiological dead space, and decreased respiratory system compliance. The **morphological** hallmarks in the acute phase are lung edema, inflammation, hyaline membranes, and alveolar hemorrhage (i.e., diffuse alveolar damage) [24].



Direktní vs indirektní ARDS?

There are many common etiologic risk factors for ARDS, which the AECC definition classified into direct and indirect lung injury categories. Although some experimental and clinical studies show modest overall differences in the inflammatory responses and radiographic patterns as well as physiologic responses to ventilatory treatment, the direct and indirect categories overlap to such a large degree that the committee decided not to include direct and indirect ARDS as distinct entities in the Berlin definition (Table 2). Identification of the risk factor leading to ARDS in an individual patient, regardless of its direct or indirect nature, rather serves to guide therapy for the underlying disease leading to ARDS.

Risk factor

Pneumonia
Non-pulmonary sepsis
Aspiration of gastric contents
Major trauma
Pulmonary contusion
Pancreatitis
Inhalational injury
Severe burns
Non-cardiogenic shock
Drug overdose
Multiple transfusions or transfusion-associated acute lung injury (TRALI)
Pulmonary vasculitis
Drowning





WIKIPEDIE
Otevřená encyklopedie

Hlavní strana
Nejlepší články
Náhodný článek
Poslední změny
Komunitní portál
Pod lipou
Náповěda
Potřebuji pomoc



Wiktionary
The free dictionary

Main Page
Community portal
Preferences
Requested entries
Recent changes
Random entry
Help
Glossary



Nejste přihlášen(a) [Diskuse](#) [Přispívky](#) [Vytvoření účtu](#) [Přihlášení](#)

[Článek](#)

[Diskuse](#)

[Číst](#)

[Editovat](#)

[Editovat zdroj](#)

[Zobrazit historii](#)

Hledat na Wikipedii

Fenotyp

Fenotyp je soubor všech pozorovatelných vlastností a znaků živého **organismu**. Představuje výsledek spolupůsobení **genotypu**, **epigenetiky** a **prostředí** čili to, jak organismus v daném **znaku** (znacích) nakonec skutečně vypadá.

Obecně rozlišujeme znaky kódované **majorgeny**, na jejichž projev ve fenotypu nemá prostředí žádný nebo téměř žádný vliv (barva očí, krevní skupiny, struktura bílkovin), a znaky kódované **minorgeny**, na jejichž projev má prostředí vliv velký (velikost rostliny, množství semen atp.).

Zhruba lze říci, že fenotyp = **genotyp** + **epigenetika** + **prostředí**.

subphenotype

English [\[edit \]](#)

Etymology [\[edit \]](#)

from *sub-* + *phenotype*

Noun [\[edit \]](#)

subphenotype (*plural* **subphenotypes**)

1. (*biology, pathology*) A subset of a **phenotype** that is characteristic of a subset of a population

Možné klasifikace subfenotypů

- Dle závažnosti
 - PaO₂/FiO₂
 - LISS
- Čas
- Extrapulmonary vs pulmonary ARDS
- Nízký vs vysoký transpulmonální tlak
- Dle CT scan ARDS study group
- *Recruitable/non-recruitable*
- *Hyper/hypo inflamatorní subfenotyp*



ARDS pathophysiology

A



Core disease
[24% of
lung tissue]

Inflammatory
spreading

Lower

Higher


Clin Chest Med 27 (2006) 559–570



71%
5%
24%

**Lower severity
and mortality**

C



55%
21%
24%

**Higher severity
and mortality**


B



Clin Chest Med 27 (2006) 559–570

Lung Recruitment in Patients with the Acute Respiratory Distress Syndrome


Luciano Gattinoni, M.D., F.R.C.P., Pietro Caironi, M.D., Massimo Cressoni, M.D., Davide Chiumello, M.D., V. Marco Ranieri, M.D., Michael Quintel, M.D., Ph.D., Sebastiano Russo, M.D., Nicolò Patroniti, M.D., Rodrigo Cornejo, M.D., and Guillermo Bugedo, M.D.



Oxygenation Response to Positive End-Expiratory Pressure Predicts Mortality in Acute Respiratory Distress Syndrome

A Secondary Analysis of the LOVS and ExPress Trials

Ewan C. Goligher^{1,2,3,4}, Brian P. Kavanagh^{1,5,6}, Gordon D. Rubenfeld^{1,2,7}, Neill K. J. Adhikari^{1,2,7}, Ruxandra Pinto⁷, Eddy Fan^{1,2,4}, Laurent J. Brochard^{1,2,8}, John T. Granton^{1,2,4}, Alain Mercat⁹, Jean-Christophe Marie Richard¹⁰, Jean-Marie Chretien¹¹, Graham L. Jones¹², Deborah J. Cook^{12,13}, Thomas E. Stewart^{1,2,4}, Arthur S. Slutsky^{1,2,4}, Maureen O. Meade^{12,13}, and Niall D. Ferguson^{1,2,3,4}





magnitude of PEEP change. Among patients in whom PEEP was increased after randomization, an increase in P/F was associated with reduced mortality (multivariable logistic regression; adjusted odds ratio, 0.80 [95% confidence interval, 0.72–0.89] per 25-mm Hg increase in P/F), particularly in patients with severe disease (baseline P/F [less-than-or-equal-to] 150 mm Hg). Changes in compliance and



Acute Respiratory Distress Syndrome Caused by Pulmonary and Extrapulmonary Disease


Different Syndromes?

LUCIANO GATTINONI, PAOLO PELOSI, PETER M. SUTER, ALESSIA PEDOTO, PAOLA VERCESI, and ALFREDO LISSONI



END-EXPIRATORY LUNG VOLUME AND ESTIMATED RECRUITMENT FOR ARDS CAUSED BY PULMONARY OR EXTRAPULMONARY DISEASE AT DIFFERENT PEEP LEVELS*



	PEEP (cm H ₂ O)			
	0	5	10	15
EELV, L				
ARDS _p	0.556 ± 0.254 [†]	0.762 ± 0.319 [†]	0.970 ± 0.381 [†]	1.150 ± 0.356 ^{†§}
ARDS _{exp}	0.602 ± 0.291 [†]	0.847 ± 0.338 [†]	1.155 ± 0.367 [†]	1.494 ± 0.340 [†]
Estimated recruitment, L				
ARDS _p		-0.002 ± 0.088	-0.003 ± 0.098 [§]	-0.031 ± 0.092 [‡]
ARDS _{exp}		0.043 ± 0.120 [†]	0.153 ± 0.200 ^{**}	0.293 ± 0.241 ^{††}



Acute Respiratory Distress Syndrome Caused by Pulmonary and Extrapulmonary Disease

Different Syndromes?

LUCIANO GATTINONI, PAOLO PELOSI, PETER M. SUTER, ALESSIA PEDOTO, PAOLA VERCESI, and ALFREDO LISSONI



Transpulmonary Pressure Describes Lung Morphology During Decremental Positive End-Expiratory Pressure Trials in Obesity*

Iacopo Fumagalli, MD^{1,2}; Lorenzo Berra, MD³; Changsheng Zhang, MD, PhD⁴; Massimiliano Pirrone, MD^{1,2}; Roberta R. De Santis Santiago, MD, PhD^{1,2}; Susimeire Gomes, MSc⁵; Federico Magni, MD⁶; Gláucia A. B. dos Santos, MSc⁷; Desmond Bennett, BA⁸; Vinicius Torsani, RRT, MSc⁹; Daniel Fisher, RRT¹⁰; Caio Morais, RRT¹¹; Marcelo B. P. Amato, MD, PhD¹²; Robert M. Kacmarek, RRT, PhD¹³

TABLE 1. Patients' Respiratory Parameters

Respiratory Parameters, <i>n</i> = 16	Baseline	Optimal PEEP	<i>p</i>
PEEP (cm H ₂ O)	12.7 ± 2.9	21.7 ± 3.7	< 0.001
Plateau pressure (cm H ₂ O)	23.8 ± 3.4	28.3 ± 4.3	< 0.001
Peak pressure (cm H ₂ O)	33.3 ± 65.1	38.8 ± 4.9	< 0.001
End-inspiratory transpulmonary pressure (cm H ₂ O)	2.5 ± 5.1	6.1 ± 3.2	0.001
End-expiratory transpulmonary pressure (cm H ₂ O)	-4.4 ± 4.6	2.1 ± 2.0	< 0.001
End-expiratory lung volume (mL/kg ideal body weight)	19.6 ± 8.0	30.4 ± 9.1	< 0.001
Elastance of the respiratory system (cm H ₂ O/L)	23.9 ± 7.1	18.6 ± 6.1	< 0.001
Elastance of the lung (cm H ₂ O/L)	16.6 ± 5.1	10.8 ± 4.3	< 0.001
Elastance of the chest wall (cm H ₂ O/L)	7.2 ± 2.9	7.7 ± 3.5	0.547
Pao ₂ /Fio ₂	163.4 ± 56.7	273.4 ± 72.1	< 0.001
Paco ₂ (mm Hg)	47.9 ± 13.4	50.9 ± 11.6	0.140



PEEP = positive end-expiratory pressure.

During all the study procedures, patients were ventilated with a tidal volume of 6.6 ± 1.0 mL/kg ideal body weight, respiratory rate of 24.1 ± 6.2 breaths/min, and Fio₂ of 66% ± 21%. Data are expressed as mean ± so, paired Student *t* test.




Transpulmonary Pressure Describes Lung Morphology During Decremental Positive End-Expiratory Pressure Trials in Obesity*

Iacopo Fumagalli, MD^{1,2}; Lorenzo Berra, MD¹; Changsheng Zhang, MD, PhD¹; Massimiliano Pirrone, MD^{1,2}; Roberta R. De Santis Santiago, MD, PhD^{1,2}; Susimeire Gomes, MSc³; Federico Magni, MD⁴; Glaucia A. B. dos Santos, MSc⁵; Desmond Bennett, BA⁶; Vinicius Torsani, RRT, MSc⁷; Daniel Fisher, RRT⁸; Caio Morais, RRT⁹; Marcelo B. P. Amato, MD, PhD¹; Robert M. Kacmarek, RRT, PhD⁸





Vliv výchozího transpulmonálního tlaku



L. Puybasset
P. Clurel
P. Gasman
P. Grenier
F. Preteux
J.-J. Rouby
and the CT Scan ARDS
Study Group

Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology


Lobární charakter



L. Pruyssset
P. Clarel
P. Gasman
P. Grenier
F. Preteux
J.-J. Rouby
and the CT Scan ARDS
Study Group

Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology



Difuzní charakter



L. Puybasset
P. Clurel
P. Gasman
P. Grenier
F. Preteux
J.-J. Rouby
and the CT Scan ARDS
Study Group

Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology

„Patchy“ charakter



L. Puybasset
 P. Gusman
 J.-C. Muller
 P. Cluzel
 P. Coriat
 J.-J. Rouby
 and the CT Scan ARDS
 Study Group

Regional distribution of gas and tissue in acute respiratory distress syndrome. III. Consequences for the effects of positive end-expiratory pressure

Table 4 PEEP-induced changes (Δ) in lung volumes in the three groups of patients (LA lobar CT attenuations, DA diffuse CT attenuations, PA patchy CT attenuations, Δ FRC change in functional residual capacity)

	LA (n = 26)	DA (n = 16)	PA (n = 29)	PEEP	p Value ^a
Δ Total volume (ml)	674 \pm 303*	510 \pm 281*	666 \pm 355*	0.0001	NS
Δ Pleural fluid (ml ⁻¹)	19 \pm 53	46 \pm 48	11 \pm 76	0.01	NS
Δ FRC (ml)	696 \pm 286*	507 \pm 282*	634 \pm 271*	0.0001	NS
Δ Volume of tissue (ml)	-22 \pm 149	3 \pm 107	32 \pm 165	NS	NS
Δ Overdistended lung areas (ml)	47 \pm 97*	2 \pm 4	18 \pm 24*	0.008	0.048
Δ Normally aerated lung areas (ml)	820 \pm 344*	601 \pm 473*	815 \pm 354*	0.0001	NS
Δ Poorly aerated lung areas (ml)	-111 \pm 169	290 \pm 298	-6 \pm 187	NS	0.0001
Δ Nonaerated lung areas (ml)	-82 \pm 68*	-383 \pm 164*	-161 \pm 151*	0.0001	0.0001

* $p < 0.05$ vs. ZEEP

^a p values refer to the repeated measures ZEEP-PEEP (PEEP) and to the interaction between the 3 groups using a two-way analysis of variance






Identification of three classes of acute respiratory distress syndrome using latent class analysis

Zhongheng Zhang

Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China






Identification of three classes of acute respiratory distress syndrome using latent class analysis

Zhongheng Zhang

Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China






Identification of three classes of acute respiratory distress syndrome using latent class analysis

Zhongheng Zhang

Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China




DOI 10.7717/peerj.4592

ΚΑΚΙΜΙ ΓΙΝΗΚ & LFHK UK





Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy

Katie R. Famous¹, Kevin Delucchi², Lorraine B. Ware^{3,4}, Kirsten N. Kangelaris⁵, Kathleen D. Liu^{6,7}, B. Taylor Thompson⁸, and Carolyn S. Calfee^{1,7}; for the ARDS Network



Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy

Katie R. Famous¹, Kevin Delucchi², Lorraine B. Ware^{3,4}, Kirsten N. Kangelaris⁵, Kathleen D. Liu^{6,7}, B. Taylor Thompson⁸, and Carolyn S. Calfee^{1,7}; for the ARDS Network



Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy

Katie R. Famous¹, Kevin Delucchi², Lorraine B. Ware^{3,4}, Kirsten N. Kangelaris⁵, Kathleen D. Liu^{6,7}, B. Taylor Thompson⁸, and Carolyn S. Calfee^{1,7}; for the ARDS Network

Table 3. Clinical Outcomes by ARDS Subphenotype

	Subphenotype 1 (n = 727)	Subphenotype 2 (n = 273)	P Value
60-d mortality, %	21	44	<0.0001
90-d mortality, %	22	45	<0.0001
Ventilator-free days, median	19	3	<0.0001

Fluid-management strategy	Subphenotype 1		Subphenotype 2		P Value
	Liberal (n = 355)	Conservative (n = 372)	Liberal (n = 142)	Conservative (n = 131)	
60-d mortality, %	24	17	39	49	0.0093
90-d mortality, %	26	18	40	50	0.0039
Ventilator-free days, median	17	21	5	0	0.35




Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Pratik Sinha^{1*}, Kevin L. Delucchi², B. Taylor Thompson³, Daniel F. McAuley^{4,5}, Michael A. Matthay^{1,6,7}, Carolyn S. Calfee^{1,6,7} and for the NHLBI ARDS Network

Class-defining variables for initial LCA model	Total population	Hypo-inflammatory (n = 468)	Hyper-inflammatory (n = 277)	p value
Heart rate (beats min ⁻¹)	118.4 (± 22.7)	114.4 (± 21.7)	124.0 (± 21.7)	< 0.001
Systolic blood pressure (mmHg)	85.4 (± 15.62)	87.2 (± 15.7)	76.6 (± 12.3)	< 0.001
Respiratory rate (breaths min ⁻¹)	32 (27–38)	33.5 (26–39.75)	35 (29–40)	< 0.001 [†]
Urine output (mL over previous 24 h)	1605 (± 1236)	1888 (± 1326)	1165 (± 967)	< 0.001
Vasopressor use at baseline	406 (54.6%)	180 (38.7%)	226 (81.6%)	< 0.001 [▲]
<hr/>				
Creatinine (mg/dL)	1.5 (± 1.2)	1.1 (± 0.73)	2.0 (± 1.16)	< 0.001
Bicarbonate (mmol/L)	21.8 (± 5.52)	22.9 (± 4.7)	18.6 (± 4.8)	< 0.001
Albumin (g/dL)	2.2 (± 0.64)	2.3 (± 0.6)	2.0 (± 0.6)	< 0.001
Bilirubin (mg/dL)	0.8 (0.5–1.4)	0.8 (± 0.8)	2.0 (± 1.9)	< 0.001
Interleukin-6 (pg/mL)	443.2 (173–1510)	281.7 (115.0–600.0)	1618.4 (517.2–3205.3)	< 0.001 [†]

Product-Limit Survival Estimates With Number of Subjects at Risk



Outcome	Hypo-inflammatory		Hyper-inflammatory		p value
	Placebo (n = 220)	Rosuvastatin (n = 248)	Placebo (n = 146)	Rosuvastatin (n = 131)	
60-day mortality, n (%)	42 (19.1%)	56 (22.6%)	49 (33.6%)	52 (39.7%)	0.877
90-day mortality, n (%)	44 (20.0%)	56 (22.6%)	52 (35.6%)	52 (39.7%)	0.953
Ventilator-free days, median (IQR)	24 (4–26)	23 (9.5–26)	16.5 (1–23)	13 (1–23)	0.697

ARDS Sub-Phenotypes

All RCT reanalyses
 uses clinical variables and biomarkers

Observational cohort analysis
 uses only biomarkers

Clinical variables

- Demographics: Age; gender; ethnicity; BMI
- ARDS aetiology: trauma; sepsis; aspiration; pneumonia or other
- Organ dysfunction: Respiratory¹; CVS²; Bilirubin; Platelets; Renal³
- Other: Temperature; Sodium; Glucose; Albumin; bicarbonate

Biomarkers



- Lung epithelial: SP-D; sRAGE
- Endothelial: ANG2; ICAM-1; vWF;
- Coagulation: PAI-1; Protein-C
- Inflammation: IL-6; IL-8; sTNFR; CRP; WCC

Biomarkers

- Lung epithelial: None
- Endothelial: E-selectin; P-selectin; ANG1/2
- Coagulation: antithrombin; D-Dimer; tPA; PAI-1
- Inflammation: fractalkine; GM-CSF; ICAM-1; IFN- γ ; IL-1 β ; IL-6; IL-8; IL-10; IL-13; TNF- α ; MMP-8; TIMP-1


Latent class analysis

Cluster analysis



	ARMA N=473	ALVEOLI N=549	FACTT N=1000	HARP N=539	SAILS N=745
% Hyper-inflammatory	32.8%	26.5%	27.2%	34.5%	37.2%
Phenotype discriminant markers	sTNFR-1; IL-6; vasopressor use	sTNFR-1; IL-6; vasopressor use	sTNFR-1; IL-8; bicarbonate	sTNFR-1; IL-6; low platelets; vasopressor	sTNFR-1; IL-8; bicarbonate

	Cohort Study N=700
% Reactive phenotype	51.9%
Phenotype discriminant markers	IL-6; IFN- γ ; ANG1/2; PAI-1



Závěry

- Populace nemocných s ARDS je heterogenní z pohledu odpovědi na ventilační postupy, odpovědi a rizikovosti tekutin a potenciálně i efektu imunomodulačních intervencí
- Posouzení morfologického typu plicní patologie, recruitability/odpovědi na PEEP a inflamatorního typu jsou důležité pro taktiku orgánové podpory nemocných s ARDS



Děkuji za pozornost.

